Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04976634
Title	Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Merck Sharp & Dohme Corp.
Indications	biliary tract cancer intrahepatic cholangiocarcinoma gallbladder cancer colorectal cancer hepatocellular carcinoma pancreatic ductal adenocarcinoma
Therapies	Belzutifan + Lenvatinib + Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA \| NZL \| NLD \| ISR \| FRA \| ESP \| BEL \| AUS